Atara Biotherapeutics Inc
Atara Biotherapeutics Inc logo
ATRA

Atara Biotherapeutics Inc (ATRA)

$4.6929.2%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$3.8
Day's Range
$4.84
$2.83
52-Week Range
$20.04
1 month return50.95%
3 month return27.4%
1 year return70.75%
5 year return75.88%

Company Information

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
OrganizationAtara Biotherapeutics Inc
Employees437
CEOPascal Touchon
IndustryHealth Technology

Analyst Recommendation

based on 15 analysts ratings

Buy
80%
Buy
13%
Hold
6%
Sell

Based on 15 Wall street analysts offering stock ratings for Atara Biotherapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 672.92%

Current

$4.69

Target

$36.25

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
12
12
13
Hold
2
2
1
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
625.6M
Book Value
3.05
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-3.63
PEG Ratio
0.0
Wall Street Target Price
30.57

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
30.76
Price/Book (mrq)
2.42
Enterprise Value
333.1M
Enterprise Value/Revenue
16.38
Enterprise Value/Ebitda
0.0

Technicals

Beta
1.81
50 Day MA
9.82
200 Day MA
14.11

Institutional Holdings

JPMorgan Chase & Co

8.77%

Baupost Group LLC

8.7%

Maverick Capital Ltd

8.41%

BlackRock Inc

8.37%

Vanguard Group Inc

7.4%

State Street Corporation

6.72%

Discover more

Frequently Asked Questions

What is Atara Biotherapeutics Inc share price today?

Can Indians buy Atara Biotherapeutics Inc shares?

How can I buy Atara Biotherapeutics Inc shares from India?

Can Fractional shares of Atara Biotherapeutics Inc be purchased?

What are the documents required to start investing in Atara Biotherapeutics Inc stocks?

What are today’s High and Low prices of Atara Biotherapeutics Inc?

What are today’s traded volumes of Atara Biotherapeutics Inc?

What is today’s market capitalisation of Atara Biotherapeutics Inc?

What is the 52 Week High and Low Range of Atara Biotherapeutics Inc?

How much percentage Atara Biotherapeutics Inc is down from its 52 Week High?

How much percentage Atara Biotherapeutics Inc is up from its 52 Week low?

What are the historical returns of Atara Biotherapeutics Inc?

Who is the Chief Executive Officer (CEO) of Atara Biotherapeutics Inc?